Literature DB >> 2340922

Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis.

A Igarashi1, K Takehara, Y Soma, K Kikuchi, Y Ishibashi.   

Abstract

Clinical significance of specific antinuclear antibodies (ANA) in Japanese patients with systemic sclerosis was studied. The patients with systemic sclerosis were classified into four groups according to ANA: (1) anticentromere antibody-positive; (2) anti-Scl-70 antibody-positive; (3) anti-nRNP antibody-positive, and (4) others. The mean score (the number of positive signs in six selected specific signs) of the patients with anti-Scl-70 antibody was significantly higher than those of the other three groups. More frequent contracture of phalanges in the patients with anti-Scl-70 antibody, less diffuse pigmentation in the patients with anti-nRNP antibody, and less pulmonary fibrosis in the patients with anticentromere antibody were revealed. As shown above, the detection of specific ANA in systemic sclerosis is clinically important.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340922     DOI: 10.1159/000248013

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  3 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis.

Authors:  H Ihn; S Sato; M Fujimoto; A Igarashi; N Yazawa; M Kubo; K Kikuchi; K Takehara; K Tamaki
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  Improvement of skin sclerosis after occurrence of anticentromere antibody in a patient with diffuse cutaneous systemic sclerosis.

Authors:  Ikuko Hayakawa; Shinichi Sato; Takeshi Echigo; Fumiaki Shirasaki; Minoru Hasegawa; Kazuhiko Takehara
Journal:  Clin Rheumatol       Date:  2004-04-09       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.